prior to now couple of years, the UK has witnessed a revolution in clinical fat‑loss therapies — in the introduction of semaglutide (Wegovy®) to the developing acceptance of tirzepatide (Mounjaro®). Now, another title is drawing focus in both equally scientific and general public well being circl